Heron Therapeutics Inc. (HRTX) — RQD Stock Rating Cockpit

Per the Roarable RQD rating, HRTX scores 37 out of 100 with a letter grade of D-, labeled "Roarable Sell — Vulnerable Balance Sheet & Flow." The five pillars are:

• Fundamental Cash Engine: 7 / 20 (ROIC -35%; FCF yield 0%). This is the weakest read on earnings power in the source data; the business is not currently generating returns on capital or free cash flow relative to its market value.
• Whale 13F Flow: 11 / 20 (institutional accumulation and options positioning). This is the strongest pillar, indicating some institutional and options-market activity, though the source data does not break out the direction or size of 13F changes.
• Insider Conviction: 3 / 20 (SEC Form 4 and Congressional PTR cluster flow). This is the lowest pillar, offering little evidence of insider-led conviction.
• Macro Regime Fit: 8 / 20 (Beta 1.0; sector sensitivity). A beta of 1.0 means the stock moves in line with the market on average, and the score reflects limited regime-based support.
• Forensic Balance Sheet: 8 / 20 (Altman Z 2.5; Piotroski F 2/9; Debt/Equity 0.5). Per the Roarable RQD rating, the Piotroski F-Score of 2 out of 9 signals weak financial strength on that scale, while the Altman Z of 2.5 and Debt/Equity of 0.5 are the more mixed inputs.

For a prospective investor evaluating the stock today, the pillar pattern points to a company where the upside case depends on improving operating economics and balance-sheet quality, neither of which is yet visible in the reported figures. The price of 0.28 sits near the low end of a 52-week range of $0.26 to $1.58, so the stock has already declined substantially within the period covered. A valuation discussion is limited because P/E, forward P/E, and EV/EBITDA are unavailable in the source data. The analysis is educational and not personalized financial advice.

Heron Therapeutics Inc. is a NASDAQ-listed issuer in the Health Care sector, within the Biotechnology: Pharmaceutical Preparations industry, per the profile. The source data does not describe its products, customers, or specific revenue model. Per the market data, the company reports a gross margin of 73.3%, which indicates the economics of its sales are high at the gross level before operating costs.

Per the SEC financials, revenue rose from $144.3M in FY 2024 to $154.9M in FY 2025, while operating income improved from $-11.5M to $-2.5M, though both periods remained negative. Per the market data, the operating margin is -1.6%, the net margin is -12.9%, and ROIC is -35%. The Roarable RQD rating records an Altman Z-Score of 2.5, a Piotroski F-Score of 2 out of 9, and a Debt/Equity ratio of 0.5. The balance sheet posture is therefore mixed: reported cash of $28.6M sits against a negative free cash flow of $-27.9M in FY 2025, and the debt line is not available in the source data.

• Scheduled catalyst: Heron Therapeutics is set to report third-quarter 2026 financial results on November 9, 2026, per multiple headlines in the news wire. This is the most time-specific event in the source data.
• Positioning signal: A MarketBeat headline reports that investors bought a high volume of put options on HRTX, which the news wire flags as a yellow-light item.
• Fundamental commentary: A kalkine.ca headline frames the company as showing acute care growth offset by oncology weakness and financial uncertainty, rated green-light in the feed.
• Market-wire items: Multiple articles (Yahoo Finance, MarketBeat, Quiver Quantitative, ad-hoc-news.de) cover institutional positioning and the upcoming results, with yellow-light tags.
• Butterfly signals: Per the Butterfly Supply-Chain Graph, the supply chain is recorded as NONE, with no butterfly links and no proprietary signals.

Per the Butterfly Supply-Chain Graph, no upstream or downstream dependencies, sector correlations, or proprietary signal links are recorded for HRTX. A prospective investor should therefore treat second-order ripple analysis as unsupported by the current dataset. The one directional item the news wire provides is that the November 9, 2026 earnings release is a near-term event that could affect sentiment across the stock and its peers, but the source data does not establish a specific supply-chain bottleneck.

• What are the company's specific products, customers, and revenue sources, given that the profile describes only sector and industry?
• What is the reported debt balance, since the debt line is N/A across all periods?
• What are the trailing EPS and valuation multiples (P/E, forward P/E, EV/EBITDA), which are absent from the market data?
• What drove the swing from a $-111.0M net loss in FY 2023 to a $-14.0M net loss in FY 2024, and what is the outlook for the November 9, 2026 results?
• What is the direction and size of recent institutional 13F changes and options positioning behind the Whale 13F Flow pillar score?